Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
99
mi
from 91732
La Jolla, CA
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
99
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
2258
mi
from 91732
Frederick, MD
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
2258
mi
from 91732
Frederick, MD
Click here to add this to my saved trials
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
1235
mi
from 91732
Mesquite, TX
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
1235
mi
from 91732
Mesquite, TX
Click here to add this to my saved trials
Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
Presence of Autoantibodies to Gastric Parietal Cells and Subsequent Vitamin B12 Deficiency in Rheumatoid Arthritis Patients
Status: Enrolling
Updated:  5/13/2014
Keesler Medical Center
1713
mi
from 91732
Keesler AFB, MS
Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
Presence of Autoantibodies to Gastric Parietal Cells and Subsequent Vitamin B12 Deficiency in Rheumatoid Arthritis Patients
Status: Enrolling
Updated: 5/13/2014
Keesler Medical Center
1713
mi
from 91732
Keesler AFB, MS
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
2258
mi
from 91732
Frederick, MD
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
2258
mi
from 91732
Frederick, MD
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
1164
mi
from 91732
Oklahoma City, OK
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
1164
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
1213
mi
from 91732
Austin, TX
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
1213
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
21
mi
from 91732
Orange, CA
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
21
mi
from 91732
Orange, CA
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from 91732
DeLand, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from 91732
DeLand, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
2201
mi
from 91732
Edgewater, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
2201
mi
from 91732
Edgewater, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from 91732
Miami Lakes, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from 91732
Miami Lakes, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
2321
mi
from 91732
Miami, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
2321
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1806
mi
from 91732
Granger, IN
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1806
mi
from 91732
Granger, IN
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
2102
mi
from 91732
Charlotte, NC
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
2102
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1966
mi
from 91732
Cinicinnati, OH
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1966
mi
from 91732
Cinicinnati, OH
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1213
mi
from 91732
Austin, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1213
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1216
mi
from 91732
Carrollton, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1216
mi
from 91732
Carrollton, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1372
mi
from 91732
Channelview, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1372
mi
from 91732
Channelview, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1235
mi
from 91732
Mesquite, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1235
mi
from 91732
Mesquite, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1227
mi
from 91732
Plano, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1227
mi
from 91732
Plano, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
1188
mi
from 91732
San Antonio, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Real Time 3D Imaging and Surrogate Bone Model
Comparison of Acetabular Shell Position Using 3D Planning vs. Standard Preoperative Planning: A Randomized Clinical Trial
Status: Enrolling
Updated:  7/29/2014
Cleveland Clinic Foundation
2033
mi
from 91732
Cleveland, OH
Real Time 3D Imaging and Surrogate Bone Model
Comparison of Acetabular Shell Position Using 3D Planning vs. Standard Preoperative Planning: A Randomized Clinical Trial
Status: Enrolling
Updated: 7/29/2014
Cleveland Clinic Foundation
2033
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Synvisc-One for Younger, Active Patients With Osteoarthritis
Long-Term Management of "Younger, Active" Patients With Pain From Early Knee Osteoarthritis With Synvisc-One (Hylan G-F 20)
Status: Enrolling
Updated:  8/4/2014
University of California
356
mi
from 91732
San Francisco, CA
Synvisc-One for Younger, Active Patients With Osteoarthritis
Long-Term Management of "Younger, Active" Patients With Pain From Early Knee Osteoarthritis With Synvisc-One (Hylan G-F 20)
Status: Enrolling
Updated: 8/4/2014
University of California
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
358
mi
from 91732
Mesa, AZ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
358
mi
from 91732
Mesa, AZ
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
352
mi
from 91732
Scottsdale, AZ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
352
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1423
mi
from 91732
Hot Springs, AR
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1423
mi
from 91732
Hot Springs, AR
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
7
mi
from 91732
Covina, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
7
mi
from 91732
Covina, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
99
mi
from 91732
La Jolla, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
99
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
21
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
329
mi
from 91732
Palo Alto, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
329
mi
from 91732
Palo Alto, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
20
mi
from 91732
Upland, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
20
mi
from 91732
Upland, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
2487
mi
from 91732
Hamden, CT
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
2487
mi
from 91732
Hamden, CT
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
2384
mi
from 91732
Lewes, DE
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
2384
mi
from 91732
Lewes, DE
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
2180
mi
from 91732
Debary, FL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
2180
mi
from 91732
Debary, FL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
2295
mi
from 91732
Jupiter, FL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
2295
mi
from 91732
Jupiter, FL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
725
mi
from 91732
Idaho Falls, ID
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
725
mi
from 91732
Idaho Falls, ID
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1579
mi
from 91732
Moline, IL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1579
mi
from 91732
Moline, IL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1606
mi
from 91732
Springfield, IL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1606
mi
from 91732
Springfield, IL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1526
mi
from 91732
Cedar Rapids, IA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1526
mi
from 91732
Cedar Rapids, IA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1339
mi
from 91732
Kansas City, KA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1339
mi
from 91732
Kansas City, KA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1975
mi
from 91732
St. Clair Shores, MI
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1975
mi
from 91732
St. Clair Shores, MI
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1573
mi
from 91732
St Louis, MO
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1573
mi
from 91732
St Louis, MO
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1572
mi
from 91732
St. Louis, MO
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1572
mi
from 91732
St. Louis, MO
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
1254
mi
from 91732
Lincoln, NE
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
1254
mi
from 91732
Lincoln, NE
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
2420
mi
from 91732
Freehold, NJ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
2420
mi
from 91732
Freehold, NJ
Click here to add this to my saved trials